Home > Insider Trading > Filing (0001209191-15-046933)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1347178	Vanda Pharmaceuticals Inc.	VNDA	Pharmaceutical Preparations (2834)	030491827

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1355537	Hristos Mihael Polymeropoulos	2200 Pennsylvania Avenue Suite 300E Washington DC 20037	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-05-21	35,806	$0.33	584,727	No	4	M	Direct
Common Stock	Disposition	2015-05-21	17,157	$10.33	567,570	No	4	S	Direct
Common Stock	Acquisiton	2015-05-22	359,815	$0.33	927,385	No	4	M	Direct
Common Stock	Disposition	2015-05-22	169,238	$10.36	758,147	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2015-05-21	35,806	$0.00	35,806	$0.33
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2015-05-22	359,815	$0.00	359,815	$0.33

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
359,815		2015-09-28	No	4	M	Direct
0		2015-09-28	No	4	M	Direct

Footnotes

Represents shares of common stock sold to cover the payment of the option exercise price and to satisfy tax obligations relating to exercise of the option, which was scheduled to expire on September 28, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.33 to $10.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.22 to $10.46, inclusive.
Became exercisable with respect to 25% of the shares on September 28, 2006, and with respect to an additional 2.08333% of the aggregate shares each month thereafter.